Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas

PLoS Computational Biology

Volumn 15, Issue 2, 2019, Pages

  van IJzendoorn, David G P ^a   Szuhai, Karoly ^a   Briaire De Bruijn, Inge H ^a   Kostine, Marie ^a   Kuijjer, Marieke L ^b   Bovée, Judith V M G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION TREES; DEEP NEURAL NETWORKS; DIAGNOSIS; DISEASES; GENE EXPRESSION; LEARNING ALGORITHMS; NEAREST NEIGHBOR SEARCH; STOCHASTIC SYSTEMS;

DIAGNOSTIC MARKERS; DIAGNOSTICS AND PROGNOSTICS; GENE EXPRESSION DATA; HDAC INHIBITORS; LEIOMYOSARCOMA; MACHINE-LEARNING; NOVEL DIAGNOSTICS; PROGNOSTIC MARKERS; SOFT TISSUE SARCOMA; THERAPEUTIC TARGETS;

TUMORS;

DOXORUBICIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; QUISINOSTAT; TRICHOSTATIN A; TUMOR MARKER; TRANSCRIPTOME;

ADULT; ALGORITHM; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER DIAGNOSIS; CANCER PROGNOSIS; CHEMOSENSITIVITY; CLINICAL OUTCOME; CLUSTER ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DRUG MECHANISM; EMBEDDING; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE REGULATORY NETWORK; GENETIC ANALYSIS; GENETIC DATABASE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; K NEAREST NEIGHBOR; LEIOMYOSARCOMA; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MORPHOLOGY; PREDICTION; RANDOM FOREST; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TISSUE MICROARRAY; VALIDATION STUDY; BIOLOGY; DRUG DEVELOPMENT; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; SARCOMA;

BIOMARKERS, TUMOR; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DRUG DISCOVERY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MACHINE LEARNING; MALE; MIDDLE AGED; PROGNOSIS; SARCOMA; TRANSCRIPTOME;

EID: 85062409093     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1006826     Document Type: Article

References (39)

1. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011/07/15. 2011; 11: 541–557. https://doi.org/10.1038/nrc3087 PMID: 21753790
2. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. 2013.
3. Abeshouse A, Adebamowo C, Adebamowo SN, Akbani R, Akeredolu T, Ally A, et al. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell. 2017/11/04. 2017; 171: 950–965.e28. https://doi.org/10.1016/j.cell.2017.10.014 PMID: 29100075
4. Van Der Maaten L, Hinton G. Visualizing Data using t-SNE [Internet]. Journal of Machine Learning Research. 2008. http://www.jmlr.org/papers/volume9/vandermaaten08a/vandermaaten08a.pdf
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001/09/13. 2001; 98: 10869–10874. https://doi.org/10.1073/pnas.191367098 PMID: 11553815
6. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. Nature Publishing Group; 2005; 435: 834. https://doi.org/10.1038/nature03702 PMID: 15944708
7. Röhrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, et al. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 2016/02/10. 2016; 131: 877–887. https://doi.org/10.1007/s00401-016-1540-6 PMID: 26857854
8. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018/03/15. 2018; 555: 469–474. https://doi.org/10. 1038/nature26000 PMID: 29539639
9. Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010/06/29. 2010; 16: 781–787. https://doi.org/10.1038/nm.2174 PMID: 20581836
10. Lesluyes T, Delespaul L, Coindre JM, Chibon F. The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms. Sci Rep. 2017/07/16. 2017; 7: 5480. https://doi.org/10.1038/s41598-017-05726-x PMID: 28710396
11. Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science (80). 2017/08/19. 2017; 357. https://doi.org/10.1126/science.aan2507 PMID: 28818916
12. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013; 45: 580–585. https://doi.org/10. 1038/ng.2653 PMID: 23715323
13. null null. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2017.
14. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. BioMed Central; 2010; 11. https://doi.org/10.1186/gb-2010-11-3-r25 PMID: 20196867
15. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018/04/ 07. 2018; 173: 400–416.e11. https://doi.org/10.1016/j.cell.2018.02.052 PMID: 29625055
16. Lausen B, Hothorn T, Bretz F, Schumacher M. Assessment of optimal selected prognostic factors. Bio-metrical J. WILEY-VCH Verlag; 2004; 46: 364–374. https://doi.org/10.1002/bimj.200310030
17. De Graaff MA, Cleton-Jansen AM, Szuhai K, Bovée JVMG. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity. Hum Pathol. 2013/03/23. 2013; 44: 1597–1604. https://doi.org/10.1016/j.humpath.2013.01.006 PMID: 23517922
18. Baranski Z, Booij TH, Cleton-Jansen AM, Price LS, van de Water B, Bovee J V, et al. Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteo-sarcoma. J Pathol. 2015/03/11. 2015; 236: 348–359. https://doi.org/10.1002/path.4528 PMID: 25757065
19. Cleven AH, Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016/03/19. 2016; 29: 582–590. https://doi.org/10.1038/modpathol.2016.45 PMID: 26990975
20. Prieto-Granada CN, Wiesner T, Messina JL, Jungbluth AA, Chi P, Antonescu CR. Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST. Am J Surg Pathol. 2015/12/10. 2016; 40: 479–489. https://doi.org/10.1097/PAS.0000000000000564 PMID: 26645727
21. Kawai A, Naito N, Yoshida A, Morimoto Y, Ouchida M, Shimizu K, et al. Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett. 2004/01/28. 2004; 204: 105–113. https://doi.org/10.1016/j.canlet.2003.09.031 PMID: 14744540
22. Chen EY, Xu H, Gordonov S, Lim MP, Perkins MH, Ma’ayan A. Expression2Kinases: mRNA profiling linked to multiple upstream regulatory layers. Bioinformatics. 2011/11/15. 2012; 28: 105–111. https://doi.org/10.1093/bioinformatics/btr625 PMID: 22080467
23. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003/11/05. 2003; 13: 2498–2504. https://doi.org/10.1101/gr.1239303 PMID: 14597658
24. Walter W, Sanchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015/05/13. 2015; 31: 2912–2914. https://doi.org/10.1093/bioinformatics/btv300 PMID: 25964631
25. Lazar A, Evans H, Shipley J. Smooth-muscle tumors. Leiomyoma of deep soft tissue. Leiomyosarcoma. WHO classification of tumours of soft tissue and bone. Lyon: IARC; 2013. p. 111–3.
26. Chau YM, Pando S, Taylor HS. HOXA11 silencing and endogenous HOXA11 antisense ribonucleic acid in the uterine endometrium. J Clin Endocrinol Metab. 2002/06/07. 2002; 87: 2674–2680. https://doi.org/10.1210/jcem.87.6.8527 PMID: 12050232
27. Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagace R, et al. MDM2 and CDK4 immu-nostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005/ 09/15. 2005; 29: 1340–1347. https://doi.org/10.1097/01.pas.0000170343.09562.39 PMID: 16160477
28. Laporte AN, Poulin NM, Barrott JJ, Wang XQ, Lorzadeh A, Vander Werff R, et al. Death by HDAC Inhibition in Synovial Sarcoma Cells. Mol Cancer Ther. 2017/09/08. 2017; 16: 2656–2667. https://doi.org/10.1158/1535-7163.MCT-17-0397 PMID: 28878027
29. Ishibe T, Nakayama T, Aoyama T, Nakamura T, Toguchida J. Neuronal differentiation of synovial sarcoma and its therapeutic application. Clin Orthop Relat Res. 2008/06/20. 2008; 466: 2147–2155. https://doi.org/10.1007/s11999-008-0343-z PMID: 18563503
30. Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, et al. The human cell atlas. Elife. 2017; 6. https://doi.org/10.7554/eLife.27041 PMID: 29206104
31. Nakamura H, Yoshida M, Tsuiki H, Ito K, Ueno M, Nakao M, et al. Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. Oncogene. 1998/03/31. 1998; 16: 1009–1019. https://doi.org/10.1038/sj.onc.1201618 PMID: 9519875
32. Bridge RS, Bridge JA, Neff JR, Naumann S, Althof P, Bruch LA. Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. J Clin Pathol. 2004. pp. 1172–1178. https://doi.org/10.1136/jcp.2004.019026 PMID: 15509679
33. Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Symmans WF, et al. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat. 2013; 137: 319–327. https://doi.org/10.1007/s10549-012-2354-4 PMID: 23208590
34. Pisanu ME, Noto A, De Vitis C, Morrone S, Scognamiglio G, Botti G, et al. Blockade of Stearoyl-CoA-desaturase 1 activity reverts resistance to cisplatin in lung cancer stem cells. Cancer Lett. 2017/08/12. 2017; 406: 93–104. https://doi.org/10.1016/j.canlet.2017.07.027 PMID: 28797843
35. Ishibe T, Nakayama T, Aoyama T, Nakamura T, Toguchida J. Neuronal Differentiation of Synovial Sarcoma and Its Therapeutic Application. Clin Orthop Relat Res. 2008. pp. 2147–2155. https://doi.org/10. 1007/s11999-008-0343-z PMID: 18563503
36. Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, et al. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun. 2018/01/13. 2018; 9: 144. https://doi. org/10.1038/s41467-017-02602-0 PMID: 29321523
37. Ou W-B, Zhu J, Eilers G, Li X, Kuang Y, Liu L, et al. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status. Oncotarget. 2015/04/19. 2015; 6: 10510–20. https://doi.org/10.18632/oncotarget.3230 PMID: 25888633
38. Bernhart E, Stuendl N, Kaltenegger H, Windpassinger C, Donohue N, Leithner A, et al. Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines. Oncotarget. 2017/11/05. 2017; 8: 77254–77267. https://doi.org/10.18632/oncotarget.20460 PMID: 29100385
39. Di Martile M, Desideri M, Tupone MG, Buglioni S, Antoniani B, Mastroiorio C, et al. Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. Oncogenesis. 2018/02/24. 2018; 7: 20. https://doi.org/10.1038/s41389-018-0026-x PMID: 29472530